Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

2026 ASCO Preview | Results from Phase III Study of Anbenitamab (KN026) Combined with HB1801 in Neoadjuvant Treatment for Breast Cancer Selected for LBA Oral Presentation

This marks a major breakthrough for China-originated innovative therapies on the international academic stage
Alphamab Oncology Announces the Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 as Neoadjuvant Treatment for Breast Cancer Has Met the Primary Endpoint

marking a historic breakthrough for bispecific antibodies in the neoadjuvant treatment of breast cancer
Alphamab Oncology Reports Full Year 2025 Financial Results and Business Highlights

Reports Full Year 2025 Financial Results and Business Highlights

Vision, Mission and Core Values

Our Mission : To enable long-term, high-quality survival for cancer patients

Our Vision : To build a biopharmaceutical company with sustained innovation and global competitiveness

Our Core Values : Innovation, Ownership, Integrity, Quality, Growth

Learn More

Glycan-specific Conjugation Platform
Bispecific Antibody Platform
Subcutaneous Formulation Platform

Revolutionary Technology in Cancer Therapeutics

This platform leverages antibody Fc glycan-specific conjugation technology, utilizing an innovative one-enzyme two-step method that simplifies processes and reduces costs. It enables the development of ADCs with highly uniform DAR, demonstrating superior serum stability, enhanced bystander effects, and a broader therapeutic window, while minimizing toxicity risks. The platform has been validated for industrial-scale production and is currently expanding to develop dual-payload ADCs with customizable DAR values. Additionally, it can be integrated with other conjugation technologies, such as thiol-based conjugation and microbial transglutaminase (mTG), to generate a diverse array of next-generation ADCs.

Learn More

Globally Leading Bispecific Antibody Development Platform

This platform integrates two core technologies: the Fc-based CRIB (Charge Repulsion Induced Bispecific) heterodimer platform and the single-domain antibody assembly platform. The CRIB technology overcomes critical CMC (Chemistry, Manufacturing, and Control) challenges in asymmetric bispecific antibody production, enabling stable manufacturing of high-purity bispecific antibodies. The single-domain antibody assembly technology allows flexible construction of quadrivalent symmetric bispecific antibodies, which enhance tumor targeting precision through dual-target synergy while minimizing off-target risks. The platform’s advantages have been validated across multiple product candidates.

Learn More

Innovation in Drug Administration Technology

Subcutaneous high concentration formulation platform has successfully overcome technical barriers in developing high-concentration (≥150 mg/mL) liquid formulations for antibody drugs, enabling long-term stable storage (24-month stability under 2-8℃conditions). It has completed the commercial formulation development for products such as KN035 (PD-L1 single-domain antibody), with patient compliance surveys showing a satisfaction rate of 92%. For ADCs, the platform offers subcutaneous formulations that reduce infusion reactions (incidence lowered to <5%) and hematologic toxicity associated with intravenous administration.

Learn More